Ketoprofen transdermal - Imprimis Pharmaceuticals

Drug Profile

Ketoprofen transdermal - Imprimis Pharmaceuticals

Alternative Names: Impracor; Ketotransdel; TDLP-110

Latest Information Update: 24 Jun 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Imprimis Pharmaceuticals
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute pain

Most Recent Events

  • 28 Mar 2014 Discontinued - Phase-III for Acute pain in USA (Transdermal)
  • 12 Nov 2013 Imprimis withdraws a phase III trial in Acute pain prior to enrolment in USA (NCT01890902)
  • 18 Apr 2013 Imprimis Pharmaceuticals plans a phase III trial for Acute pain (9148590; NCT01890902)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top